Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H10O4 |
Molecular Weight | 194.184 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(\C=C\C(O)=O)=CC=C1O
InChI
InChIKey=KSEBMYQBYZTDHS-HWKANZROSA-N
InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+
Molecular Formula | C10H10O4 |
Molecular Weight | 194.184 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20185318 |
9.78 µM [Ki] | ||
Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20185318 |
9.87 µM [Ki] | ||
Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20185318 |
7.41 µM [Ki] | ||
Target ID: CHEMBL3510 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20185318 |
9.43 µM [Ki] | ||
Target ID: CHEMBL4789 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20185318 |
7.04 µM [Ki] | ||
Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20185318 |
2.89 µM [Ki] | ||
Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20185318 |
2.4 µM [Ki] | ||
Target ID: CHEMBL3650 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26473837 |
3.78 µM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Isolation and quantitation of steroids from normal human amniotic fluid. | 1968 Aug |
|
Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. | 1998 Jan-Feb |
|
Investigation of the potential of capillary electrophoresis with off-line matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for clinical analysis: examination of a glycoprotein factor associated with cancer cachexia. | 1999 Feb 15 |
|
Bioactive constituents of the bark of Parkia biglobosa. | 2000 Apr |
|
In vitro and in vivo evaluation of caffeic and ferulic acids as topical photoprotective agents. | 2000 Apr 10 |
|
Metabolites of orally administered Perilla frutescens extract in rats and humans. | 2000 Jan |
|
Antioxidant effect of ferulic acid in isolated membranes and intact cells: synergistic interactions with alpha-tocopherol, beta-carotene, and ascorbic acid. | 2004 Apr 21 |
|
Rye bran bread intake elevates urinary excretion of ferulic acid in humans, but does not affect the susceptibility of LDL to oxidation ex vivo. | 2004 Aug |
|
Ferulic acid inhibits endothelial cell proliferation through NO down-regulating ERK1/2 pathway. | 2004 Dec 15 |
|
Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. | 2004 Jul 2 |
|
Antitubercular constituents of Valeriana laxiflora. | 2004 Jun |
|
Influence of ferulic acid on circulatory prooxidant-antioxidant status during alcohol and PUFA induced toxicity. | 2004 Sep |
|
Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. | 2004 Sep 19 |
|
Interactions of human serum albumin with chlorogenic acid and ferulic acid. | 2004 Sep 24 |
|
Ferulic acid, a natural protector against carbon tetrachloride-induced toxicity. | 2005 Aug |
|
Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans. | 2005 Feb |
|
Antioxidant and antigenotoxic effects of plant cell wall hydroxycinnamic acids in cultured HT-29 cells. | 2005 Jun |
|
Modulation of hepatic phase II phenol sulfotransferase and antioxidant status by phenolic acids in rats. | 2006 Aug |
|
Synergistic salubrious effect of ferulic acid and ascorbic acid on membrane-bound phosphatases and lysosomal hydrolases during experimental myocardial infarction in rats. | 2006 Dec 23 |
|
Synergistic interactions of ferulic acid with ascorbic acid: its cardioprotective role during isoproterenol induced myocardial infarction in rats. | 2006 Feb |
|
Attenuation of abnormalities in the lipid metabolism during experimental myocardial infarction induced by isoproterenol in rats: beneficial effect of ferulic acid and ascorbic acid. | 2006 May |
|
Analysis of interaction property of bioactive components in Danggui Buxue Decoction with protein by microdialysis coupled with HPLC-DAD-MS. | 2007 Jun 1 |
|
Predicting the biological activities of 2-methoxyphenol antioxidants: effects of dimers. | 2007 Mar-Apr |
|
Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin. | 2008 Aug 8 |
|
Synthesis of trans-caffeate analogues and their bioactivities against HIV-1 integrase and cancer cell lines. | 2008 Dec 15 |
|
Influence of ferulic acid on nicotine-induced lipid peroxidation, DNA damage and inflammation in experimental rats as compared to N-acetylcysteine. | 2008 Jan 20 |
|
Anti-atherogenic property of ferulic acid in apolipoprotein E-deficient mice fed Western diet: comparison with clofibrate. | 2010 Aug-Sep |
|
Restoration of altered microRNA expression in the ischemic heart with resveratrol. | 2010 Dec 23 |
|
Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. | 2010 Dec 5 |
|
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines. | 2010 Oct 6 |
|
Ferulic acid protects against carbon tetrachloride-induced liver injury in mice. | 2011 Apr 11 |
|
Celastrol inhibits Tat-mediated human immunodeficiency virus (HIV) transcription and replication. | 2011 Jul 29 |
|
Interaction of cinnamic acid derivatives with commercial hypoglycemic drugs on 2-deoxyglucose uptake in 3T3-L1 adipocytes. | 2011 Sep 28 |
|
Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus. | 2013 |
|
Anticonvulsant and behavioral effects observed in mice following treatment with an ester derivative of ferulic acid: Isopentyl ferulate. | 2015 Dec 5 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 20:00:10 GMT 2023
by
admin
on
Sat Dec 16 20:00:10 GMT 2023
|
Record UNII |
AVM951ZWST
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
1643 (Number of products:16)
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
||
|
FDA ORPHAN DRUG |
886422
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
445858
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
537-98-4
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
2821
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
100000125953
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
1270311
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
AVM951ZWST
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
674320
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
214-490-0
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
1135-24-6
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
51986
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
DB07767
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
FERULIC ACID
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
17620
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
1368647
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
AVM951ZWST
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
C004999
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
7663
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | |||
|
m5359
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB32804
Created by
admin on Sat Dec 16 20:00:10 GMT 2023 , Edited by admin on Sat Dec 16 20:00:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
ASSAY (HPLC)
|
||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
98.1% reaction on PG synthase w/10.0 mM conc. of compound
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |